As previously reported, Maxim analyst Justin Lumiere upgraded Keryx Biopharmaceuticals to Buy from Hold after the FDA approved its application for a second contract manufacturer, Patheon, to make Auryxia. The analyst, who believes from management's call that production will likely be in place by 1Q17 and that the company will be building supply now to make sure there are no further interruptions once Auryxia is reintroduced, sees 2017 U.S. sales of the drug doubling to $44M from the $22M he projects for 2016. Lumiere reinstated a $7 price target on Keryx shares.